Shibuya chooses ADVA to deliver encrypted services to Nordic banks
16.2.2023 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Shibuya is deploying its open optical technology to deliver secure managed services to leading banks across the Nordics and Baltics. The new network features robust optical encryption cards from Adva Network Security for critical data protection. Shibuya, a leading Swedish IT service provider and ADVA’s long-term Select partner, is using the solution to offer highly available connectivity with end-to-end data protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005611/en/
ADVA’s technology is helping banks securely transport mission-critical data throughout the Nordic and Baltic regions. (Photo: Business Wire)
“For our financial customers, security couldn’t be more crucial. That’s why we’re ensuring that our managed services protect data in motion with the most robust defense available. At Shibuya, we specialize in delivering secure and sustainable IT environments, and ADVA’s solutions are a perfect fit,” said Jessica Liljefors, business area manager at ShibuyaCare, Shibuya. “Adva Network Security‘s encryption technology and the unique experience of its team help us deliver the strongest possible protection and offer complete peace of mind to our banking clients and their customers. Combined with our extensive cybersecurity measures, local data centers near the customers and 24/7 IT support, we can provide the high-end services demanded by the financial sector.”
The new solution safeguards mission-critical financial traffic using ConnectGuard™ Optical encryption technology provided by Adva Network Security. The technology protects data in-flight to the strictest regulatory requirements with minimal impact on throughput. Part of the new infrastructure is built on the ADVA FSP 3000 TeraFlex™ platform, which uses ultra-flexible modulation with fractional QAM. This supports 600Gbit/s streams while ensuring the lowest possible cost per bit. ADVA’s technology also supports the latest generations of low-latency Fibre Channel, empowering financial network operators to keep up with the requirements of new server and storage technologies – a key consideration for Shibuya and some of its enterprise customers.
“The reputation of today’s financial institutions is built on trust and confidence. By enabling banking customers to harness our TeraFlex™ terminal and enterprise cards, Shibuya is ensuring that Nordic financial enterprises can protect the integrity of highly sensitive data wherever it happens to be in the network. What’s more, our technology delivers the highest levels of performance while also reducing cost per bit,” commented Hartmut Müller-Leitloff, SVP of sales EMEA at ADVA. “And for major banks, being able to utilize the best available storage area network protocols is also key for meeting new business continuity needs and staying operational in the face of any disruption.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Shibuya
Shibuya creates secure and sustainable IT environments for a digital Sweden. The company is one of the country’s premier operators in business-critical IT and delivers services in, among other things, data center infrastructure and IT operation, hybrid cloud solutions, cyber security, 24/7 IT service and support, communication, application operations and third-party services. Shibuya has strategic partnerships with leading manufacturers and reference solutions with several of the Nordics’ most demanding IT operations in both the private and public sectors. The company is certified according to ISO 14001, 9001 and 27001 standards and is part of the Pulsen Group. www.shibuya.se
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005611/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom